Atea Pharmaceuticals Inc. (AVIR)
NASDAQ: AVIRHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
AVIR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $401.83M
- EPS (TTM)
- -$2.09
- Dividend yield
- None
- 52-week range
- 2.87 – 6.45
- Day range
- 4.99 – 5.23
- Volume / Avg
- 264.76K / 298.92K
- Beta
- —
- Shares outstanding
- 80.20M
52-week range
AVIR stock today
Shares of Atea Pharmaceuticals (AVIR) finished lower on Oct 7 at $5.01, a drop of 1.18% or $0.06 per share, versus the S&P 500's 0.22% decline. At this level, AVIR sits in the middle of its 52-week range of $2.87 to $6.45: 22.3% below the high, set on Mar 10, 2026 and 74.6% above the low. AVIR is up 40.3% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 68.7%.
Atea Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.09), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Atea Pharmaceuticals
Company profileAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jean-Pierre Sommadossi Ph.D.
- Headquarters
- Boston, MA
- Employees
- 55
- IPO year
- 2020
- Website
- ateapharma.com
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$9.42+88.02%
- Strong buy 0
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Atea Pharmaceuticals peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EIKNEikon Therapeutics Inc. | 7.54 | +0.40% | $408.40M | vs AVIR |
| ZURAZura Bio Limited Class A | 4.17 | +5.30% | $399.61M | vs AVIR |
| YDESYD Bio Limited | 5.88 | -4.39% | $416.49M | vs AVIR |
| EDITEditas Medicine Inc. | 2.75 | +0.73% | $422.35M | vs AVIR |
| RZLTRezolute Inc. | 4.38 | +1.39% | $423.64M | vs AVIR |
| DMACDiaMedica Therapeutics Inc. | 7.99 | -1.72% | $430.87M | vs AVIR |
| KYTXKyverna Therapeutics Inc. | 6.17 | +0.16% | $381.57M | vs AVIR |
| AGMBAgomAb Therapeutics NV ADR | 8.80 | -0.45% | $433.38M | vs AVIR |
Indexes, lists and sector
Appears in lists
Atea Pharmaceuticals stock FAQ
What is Atea Pharmaceuticals's stock price today?
AVIR last traded at $5.01 as of Oct 7, 4:00 PM EDT, down 1.18% on the day. Prices are delayed at least 15 minutes.
Who is Atea Pharmaceuticals's CEO?
Dr. Jean-Pierre Sommadossi Ph.D. is the chief executive officer of Atea Pharmaceuticals Inc., which has about 55 employees.
What is the AVIR 52-week high?
The 52-week high for AVIR is $6.45 and the 52-week low is $2.87. The stock is currently 22.3% below its high.